Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor–associated major bleeding

Miriam Kimpton, Deborah M. Siegal

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 204–208.

https://doi.org/10.1182/hematology.2019000074

Published: 2019

Journal Articles

Sickle cell disease: a comprehensive program of care from birth

Mariane de Montalembert, Léon Tshilolo, Slimane Allali

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 490–495.

https://doi.org/10.1182/hematology.2019000053

Published: 2019

Journal Articles

What is the role of screening for pulmonary hypertension in adults and children with sickle cell disease?

Shaina M. Willen, Mark T. Gladwin

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 431–434.

https://doi.org/10.1182/asheducation-2017.1.431

Published: 2017

Journal Articles

Chronic organ failure in adult sickle cell disease

Elliott Vichinsky

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 435–439.

https://doi.org/10.1182/asheducation-2017.1.435

Published: 2017

Journal Articles

Prevention of central nervous system sequelae in sickle cell disease without evidence from randomized controlled trials: the case for a team-based learning collaborative

Michael R. DeBaun, Allison A. King

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 632–639.

https://doi.org/10.1182/asheducation-2016.1.632

Published: 2016

Journal Articles

Venous thromboembolism and stroke in pregnancy

Kelley McLean, Mary Cushman

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 243–250.

https://doi.org/10.1182/asheducation-2016.1.243

Published: 2016

Journal Articles

Perinatal thrombosis: implications for mothers and neonates

Sarah H. O'Brien

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 48–52.

https://doi.org/10.1182/asheducation-2015.1.48

Published: 2015

Journal Articles

Red cell exchange: special focus on sickle cell disease

Haewon C. Kim

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 450–456.

https://doi.org/10.1182/asheducation-2014.1.450

Published: 2014

Journal Articles

Reversing targeted oral anticoagulants

Maureane Hoffman, Dougald M. Monroe

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 518–523.

https://doi.org/10.1182/asheducation-2014.1.518

Published: 2014

Journal Articles

Smoothing the crescent curve: sickle cell disease

Julie-An Talano, Mitchell S. Cairo

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 468–474.

https://doi.org/10.1182/asheducation-2014.1.468

Published: 2014

Journal Articles

Does hydroxyurea prevent pulmonary complications of sickle cell disease?

Tyler W. Buckner, Kenneth I. Ataga

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 432–437.

https://doi.org/10.1182/asheducation-2014.1.432

Published: 2014

Journal Articles

Secondary Prevention of Overt Strokes in Sickle Cell Disease: Therapeutic Strategies and Efficacy

Michael R. DeBaun

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 427–433.

https://doi.org/10.1182/asheducation-2011.1.427

Published: 2011

Journal Articles

What Is the Evidence for Using Hydroxyurea for Secondary Stroke Prevention?

Jeffrey D. Lebensburger, Michael R. DeBaun, Alexis A. Thompson

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 440–442.

https://doi.org/10.1182/asheducation-2011.1.440

Published: 2011

Journal Articles

Warfarin Versus New Agents: Interpreting the Data

Jack Ansell

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 221–228.

https://doi.org/10.1182/asheducation-2010.1.221

Published: 2010

Journal Articles

Evaluation and management of stroke

Brett L. Cucchiara

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 293–301.

https://doi.org/10.1182/asheducation-2009.1.293

Published: 2009

Journal Articles

Novel Small Molecule Therapeutics for Sickle Cell Disease: Nitric Oxide, Carbon Monoxide, Nitrite, and Apolipoprotein A-I

Gregory J. Kato

Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 186–192.

https://doi.org/10.1182/asheducation-2008.1.186

Published: 2008

Journal Articles

Limitations of Clinical Trials in Sickle Cell Disease: A Case Study of the Multi-center Study of Hydroxyurea (MSH) Trial and the Stroke Prevention (STOP) Trial

Michael R. DeBaun, Joshua J. Field

Hematology Am Soc Hematol Educ Program (2007) 2007 (1): 482–488.

https://doi.org/10.1182/asheducation-2007.1.482

Published: 2007

Journal Articles

Prevention and Management of Stroke in Sickle Cell Anemia

Orah S. Platt

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 54–57.

https://doi.org/10.1182/asheducation-2006.1.54

Published: 2006

Journal Articles

An Evidence-Based Approach to the Treatment of Adults with Sickle Cell Disease

Richard Lottenberg, Kathryn L. Hassell

Hematology Am Soc Hematol Educ Program (2005) 2005 (1): 58–65.

https://doi.org/10.1182/asheducation-2005.1.58

Published: 2005

Journal Articles

The Cardiovascular Pharmacology of COX-2 Inhibition

Susanne Fries, Tilo Grosser

Hematology Am Soc Hematol Educ Program (2005) 2005 (1): 445–451.

https://doi.org/10.1182/asheducation-2005.1.445

Published: 2005

NARROW

Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor–associated major bleeding

Sickle cell disease: a comprehensive program of care from birth

What is the role of screening for pulmonary hypertension in adults and children with sickle cell disease?

Chronic organ failure in adult sickle cell disease

Prevention of central nervous system sequelae in sickle cell disease without evidence from randomized controlled trials: the case for a team-based learning collaborative

Venous thromboembolism and stroke in pregnancy

Perinatal thrombosis: implications for mothers and neonates

Red cell exchange: special focus on sickle cell disease

Reversing targeted oral anticoagulants

Smoothing the crescent curve: sickle cell disease

Does hydroxyurea prevent pulmonary complications of sickle cell disease?

Secondary Prevention of Overt Strokes in Sickle Cell Disease: Therapeutic Strategies and Efficacy

What Is the Evidence for Using Hydroxyurea for Secondary Stroke Prevention?

Warfarin Versus New Agents: Interpreting the Data

Evaluation and management of stroke

Novel Small Molecule Therapeutics for Sickle Cell Disease: Nitric Oxide, Carbon Monoxide, Nitrite, and Apolipoprotein A-I

Limitations of Clinical Trials in Sickle Cell Disease: A Case Study of the Multi-center Study of Hydroxyurea (MSH) Trial and the Stroke Prevention (STOP) Trial

Prevention and Management of Stroke in Sickle Cell Anemia

An Evidence-Based Approach to the Treatment of Adults with Sickle Cell Disease

The Cardiovascular Pharmacology of COX-2 Inhibition

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only